Biotech Values

[puravida]

Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

'New York-based Bristol-Myers and Nektar agreed to a $1.85 billion strategic development and commercialization collaboration to develop medicines, including NKTR-214, for multiple cancer types in February 2018.'

https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-and-bristol-myers-squibb-announce-us-fda